R&D channel feed – Endpoints News

R&D channel feed

Regeneron leaps into the blockbuster race to develop off-the-shelf immune cell cancer therapies

9 years ago

Pfizer boosts its gene therapy work, bags upstart Bamboo in $645M buyout deal

9 years ago

Microcap MEI joins the long lineup of cancer biopharmas to land a ‘breakthrough’

9 years ago

Biogen, Ionis declare an early victory for PhIII spinal muscular atrophy study, triggering $75M payout

9 years ago

Ex-Allergan CEO David Pyott backs a biotech startup alongside Takeda, PhI trial set to launch

9 years ago

Google’s Verily and GlaxoSmithKline hatch a $713M plan to spark a biorevolution

9 years ago

Tokai quickly tosses most of its staff after PhIII cancer drug fails

9 years ago

Bristol-Myers takes a commanding lead over Merck in the first stretch of a blockbuster race

9 years ago

Takeda overhauls R&D, focusing on Boston and Japan in global reorganization

9 years ago

NewLink axes 100 staffers, shrinks pipeline in wake of a PhIII debacle

9 years ago

Hey, wait a second. What about Roche’s PhIII hemophilia A drug?

9 years ago

Microbiome pioneer Seres crushed as lead drug flops in PhII

9 years ago

The biopharma week in review: Thumbs Up, Thumbs Down

9 years ago

From boom to swoon: Biotech IPOs fade fast in Q2

9 years ago

AstraZeneca surges on Soriot’s upbeat assessment of its pipeline

9 years ago

Eli Lilly’s new CEO is ready to start partnering on R&D

9 years ago

The biggest winners and losers in the 2016 game of blockbusters

9 years ago

Deal Watch, Amgen: ‘We’ve got a number of pretty interesting prospects’

9 years ago

Pointing to a cure, BioMarin reports impressive trial results for hemophilia A gene therapy

9 years ago

Pfizer bags a Langer platform, buys Bind assets with a $40M bid

9 years ago

Beefing up its respiratory pipeline, GlaxoSmithKline bags J&J drug in $230M deal

9 years ago

TauRx takes a slice of positive data and claims success after a failed PhIII Alzheimer’s study

9 years ago

After a tough haul, John Lechleiter is stepping down at Eli Lilly

9 years ago

Eyeing a potential market launch, Astellas orders up a $95M third course of Cytokinetics’ pipeline

9 years ago

First page Previous page 323 324 325326327 328 329 Next page Last page